Hindustan Bio Sciences Share Price Today

Hindustan Bio Sciences Q2FY27 Results: Profit turns positive at ₹31 lakh

Hindustan Bio Sciences reported a Q2FY27 net profit of ₹31.04 lakh, turning around from a loss of ₹5.85 lakh in Q2FY26. Total income surged to ₹85.04 lakh, driven primarily by other income of ₹82.21 lakh rather than core operations. Revenue from operations remained minimal at ₹2.83 lakh, while total expenses rose to ₹54.00 lakh. Company Secretary Shailendra Vyas resigned effective October 31, 2026, citing career opportunities outside the organization. Unaudited results were published in newspapers on November 3, 2026, following board approval on October 31, 2026.

Hindustan Bio Sciences shareholders approve share capital reduction

Shareholders approved the Scheme of Reduction of Share Capital via special resolution. Uma Jampana reappointed as director after retiring by rotation. Audited financial statements for FY26 adopted without any audit qualifications. 39 shareholders attended physically out of 12,039 on record.

Hindustan Bio Sciences approves capital reduction and share consolidation

Board approves capital reduction scheme to set off ₹1.13 crore of accumulated losses. Paid-up capital to drop from ₹2.05 crore to ₹92.26 lakh via share cancellation. Shares to be consolidated from ₹2 face value to ₹10 face value. Promoter to forgo fractional shares arising from rounding off. Scheme requires NCLT and shareholder approval.

Hindustan Bio Sciences posts ₹11.29 lakh loss in Q1FY27 on zero revenue

Hindustan Bio Sciences Limited posted a standalone net loss of ₹11.29 lakh for Q1FY27, reversing the ₹1.40 lakh profit from Q1FY26. The loss stems from zero operational revenue against persistent fixed expenses of ₹11.29 lakh, primarily employee benefits. The Board approved the results on July 31, 2026, and scheduled the 34th AGM for September 30, 2026.

Hindustan Bio Sciences publishes audited results for FY26

Hindustan Bio Sciences Limited has published its audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. The results were disclosed in newspapers on June 1 and June 2, 2026, and are available on the company website.

Hindustan Bio Sciences files FY26 compliance report

Hindustan Bio Sciences Limited filed its Annual Secretarial Compliance Report for FY26, confirming full compliance with SEBI LODR regulations. The report, dated May 16, 2026, noted no deviations or non-compliances across statutory provisions, including insider trading and related party transactions.